rs370380553
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 3P and 3B. PM2PP2BP4_ModerateBP6
The NM_003072.5(SMARCA4):c.4254C>A(p.Asp1418Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_003072.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMARCA4 | NM_001387283.1 | c.4350C>A | p.Asp1450Glu | missense_variant | Exon 31 of 36 | ENST00000646693.2 | NP_001374212.1 | |
SMARCA4 | NM_003072.5 | c.4254C>A | p.Asp1418Glu | missense_variant | Exon 30 of 35 | ENST00000344626.10 | NP_003063.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMARCA4 | ENST00000646693.2 | c.4350C>A | p.Asp1450Glu | missense_variant | Exon 31 of 36 | NM_001387283.1 | ENSP00000495368.1 | |||
SMARCA4 | ENST00000344626.10 | c.4254C>A | p.Asp1418Glu | missense_variant | Exon 30 of 35 | 1 | NM_003072.5 | ENSP00000343896.4 | ||
SMARCA4 | ENST00000643549.1 | c.4260C>A | p.Asp1420Glu | missense_variant | Exon 30 of 35 | ENSP00000493975.1 | ||||
SMARCA4 | ENST00000541122.6 | c.4164C>A | p.Asp1388Glu | missense_variant | Exon 30 of 35 | 5 | ENSP00000445036.2 | |||
SMARCA4 | ENST00000643296.1 | c.4164C>A | p.Asp1388Glu | missense_variant | Exon 29 of 34 | ENSP00000496635.1 | ||||
SMARCA4 | ENST00000644737.1 | c.4164C>A | p.Asp1388Glu | missense_variant | Exon 29 of 34 | ENSP00000495548.1 | ||||
SMARCA4 | ENST00000589677.5 | c.4164C>A | p.Asp1388Glu | missense_variant | Exon 30 of 35 | 5 | ENSP00000464778.1 | |||
SMARCA4 | ENST00000643995.1 | c.3675C>A | p.Asp1225Glu | missense_variant | Exon 27 of 32 | ENSP00000496004.1 | ||||
SMARCA4 | ENST00000644963.1 | c.2907C>A | p.Asp969Glu | missense_variant | Exon 23 of 28 | ENSP00000495599.1 | ||||
SMARCA4 | ENST00000644065.1 | c.2889C>A | p.Asp963Glu | missense_variant | Exon 22 of 27 | ENSP00000493615.1 | ||||
SMARCA4 | ENST00000642350.1 | c.2748C>A | p.Asp916Glu | missense_variant | Exon 22 of 27 | ENSP00000495355.1 | ||||
SMARCA4 | ENST00000643857.1 | c.2616C>A | p.Asp872Glu | missense_variant | Exon 21 of 25 | ENSP00000494159.1 | ||||
SMARCA4 | ENST00000538456.4 | c.420C>A | p.Asp140Glu | missense_variant | Exon 4 of 8 | 3 | ENSP00000495197.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Rhabdoid tumor predisposition syndrome 2 Uncertain:1
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glutamic acid amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with SMARCA4-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces aspartic acid with glutamic acid at codon 1450 of the SMARCA4 protein (p.Asp1450Glu). The aspartic acid residue is highly conserved and there is a small physicochemical difference between aspartic acid and glutamic acid. -
Hereditary cancer-predisposing syndrome Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at